Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + Paclitaxel in Advanced TNBC
NCT03057600Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in triple-negative breast cancer (TNBC), sponsored by Calithera Biosciences. Started May 2017; status: completed.
02
Drugs
telaglenastat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03057600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057600.